# CC-486 and Venetoclax for Acute Myeloid Leukemia

> **NCT05287568** · PHASE1 · RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 35 (estimated)

## Conditions studied

- AML

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** CC-486

## Key facts

- **NCT ID:** NCT05287568
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-19
- **Primary completion:** 2027-03-23
- **Final completion:** 2029-03
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05287568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05287568, "CC-486 and Venetoclax for Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05287568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*